
European Journal of Medicinal Chemistry (2021)
Update date:2022-07-30
Topics:
Kraj?ovi?ová, Soňa
Jorda, Radek
Vanda, David
Soural, Miroslav
Kry?tof, Vladimír
Herein, we report an efficient synthetic approach towards trisubstituted imidazo [4,5-c]pyridines designed as inhibitors of Bruton's tyrosine kinase (BTK). Two alternative synthetic routes for the simple preparation of desired compounds with variable substitutions at the N1, C4, C6 positions were introduced with readily available building blocks. Further, the developed synthetic approach was feasible for isomeric compounds bearing imidazo [4,5-b]pyridine scaffolds. In contrast to expectations based on previous studies, the imidazo [4,5-c]pyridine inhibitor exhibited a significantly higher activity against BTK compared to its imidazo [4,5-b]pyridine isomer. An inherent SAR study in the series of imidazo [4,5-c]pyridine compounds revealed a remarkably high tolerance of C6 substitutions for both hydrophobic and hydrophilic substituents. Preliminary cellular experiments indicated selective BTK targeting in Burkitt lymphoma and mantle cell lymphoma cell lines. The inhibitors could thus serve as starting points for further development, eventually leading to BTK inhibitors that could be used after ibrutinib failure.
Contact:+86-518-81061113
Address:No. 8 Lingzhou Road, Lianyungang, Jiangsu, China
Xi'an HO-SHINE Bio-Technology Co., Ltd
Contact:+86 (29) 8248-5435/18292020086
Address:No.6 Shiyuan Road Xian City Shaanxi Province, 710048 China
NANCHANG QINZHI SCI&TEC.CO.,LTD(expird)
Contact:+86-13687004106
Address:Hero South Road,Hero Zone,Nanchang,Jiangxi,China
Nanjing Norris Pharm Technology Co., Ltd.
Contact:+86-13901585132
Address:2 Qiande Road, Jiangning sciencepark Hi-Tech Zone, Nanjing, P.R.China
Contact:+31-24-3886056
Address:Binderskampweg 29 Unit 36
Doi:10.1016/j.tetlet.2009.02.011
(2009)Doi:10.1021/acs.jafc.9b05507
(2019)Doi:10.1002/chem.201503123
(2015)Doi:10.1055/s-0030-1260199
(2011)Doi:10.1039/P19870002411
(1987)Doi:10.1039/b819959k
(2009)